MAP2K7 and cancer: ERK is the culminating kinase in the MAPK pathway cascade, providing a suitable therapeutic option for KRAS-mutant cancer patients resistant to RAF or MEK inhibitors (Hatzivassiliou et al., 2012; Morris et al., 2013).